Slingshot Therapeutics Limited (“Slingshot”), the Syncona Accelerator, built to identify and advance de-risked therapeutic programmes from the work of leading academic researchers, today announces the appointment of Ed Savory as Slingshot’s Head of Chemistry. Ed will lead all aspects of Slingshot’s chemistry initiatives, overseeing the strategic vision and execution of the company’s chemistry programmes, and working closely with CROs and academic scientists to ensure a seamless integration of chemistry into the broader research strategy. The appointment will drive both the expansion of Slingshot’s pipeline and the acceleration of its programmes towards the clinic.
Ed has more than 22 years’ experience advancing drug development programmes in the industry across VC-funded start-ups and mid-sized UK, European and US-based biotech companies. Prior to joining Slingshot, Ed was Senior Vice President, Drug Discovery at BenevolentAI where he led a multi-disciplinary team identifying candidate drugs for development.
He has also held several roles at Proximagen (Upsher-Smith), including Head of Exploratory Research, and Cambridge Biotechnology (Biovitrum). Ed has a PhD from Oxford University, specialising in asymmetric synthesis using chiral auxiliaries and novel methodologies.
Richard Wooster, Chief Scientific Officer and Director, Slingshot, said: “We’re delighted to welcome Ed to the Slingshot team as the Head of Chemistry. Ed’s breadth and depth of experience will be invaluable to the Company in its mission to accelerate exceptional academic science towards tangible solutions for patients.”
Ed Savory, Head of Chemistry, Slingshot, added: “I’m excited to join the Slingshot team as they bridge the gap between academic innovation and the clinical development of novel medicines. I’m looking forward to working alongside leading academic researchers to advance world-class therapeutic programmes, like Apini, and diligence new opportunities to build Slingshot’s pipeline.”
ENDS
For more information, please contact:
- Slingshot Therapeutics:info@slingshot-accelerator.co.uk
- FTI Consulting: Tim Stamper / Lucy Molloy / SlingshotTx@fticonsulting.com
About Slingshot
Slingshot Therapeutics Limited, the Syncona Accelerator, was built to identify and advance de-risked therapeutic programmes from the work of leading academic researchers.
Slingshot provides an innovative platform with access to centralised expertise, resource, funding and operational support to accelerate exceptional academic science into attractive biotech assets ready for clinical development. Slingshot aims to accumulate a pipeline of small molecule programmes across a range of therapeutics areas where there is significant unmet medical need, identified from world-leading academic institutions in the UK, US and Europe. For more information please visit: slingshot-accelerator.co.uk